| Methods |
2‐week placebo run‐in; inclusion criteria= DBP 100‐115 mm Hg after run‐in; 6‐week double‐blind treatment |
| Participants |
Ramipril 2.5 mg: n=40(26 males,14 females); mean age=47(10) years; baseline SBP=159(15) mm Hg, DBP=107(5) mm Hg;
Ramipril 5 mg: n=40(23 males,17 females); mean age=48(8) years; baseline SBP=159(13) mm Hg, DBP=107(6) mm Hg;
Ramipril 10 mg: n=40(24 males,16 females); mean age=47(9) years; baseline SBP=160(14) mm Hg, DBP=109(5) mm Hg;
Placebo: n=40(22 males,18 females); mean age=46(10) years; baseline SBP=161(17) mm Hg, DBP=109(5) mm Hg |
| Interventions |
Ramipril 2.5 mg once daily;
Ramipril 5 mg once daily;
Ramipril 10 mg once daily;
Placebo;
administered in the morning |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change reported, SD of change not reported, endpoint BP and SD not reported; imputed baseline SBP SD for SBP SD of change; imputed overall trial mean DBP SD of change; BP data from Figures 1 and 2, p. 669; Jadad score=3; funding source= Cassella AG |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
